KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $723.4 million.

  • Alnylam Pharmaceuticals' Change in Acquisitions & Divestments rose 7079.99% to $723.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 3556.28%. This contributed to the annual value of $1.6 billion for FY2024, which is 114.98% up from last year.
  • Alnylam Pharmaceuticals' Change in Acquisitions & Divestments amounted to $723.4 million in Q3 2025, which was up 7079.99% from $332.5 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $723.4 million during Q3 2025, with a 5-year trough of $291.4 million in Q4 2021.
  • For the 5-year period, Alnylam Pharmaceuticals' Change in Acquisitions & Divestments averaged around $442.1 million, with its median value being $423.5 million (2024).
  • In the last 5 years, Alnylam Pharmaceuticals' Change in Acquisitions & Divestments plummeted by 4182.11% in 2021 and then skyrocketed by 10748.67% in 2022.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Change in Acquisitions & Divestments stood at $291.4 million in 2021, then soared by 107.49% to $604.7 million in 2022, then tumbled by 39.84% to $363.8 million in 2023, then grew by 21.77% to $443.0 million in 2024, then surged by 63.29% to $723.4 million in 2025.
  • Its Change in Acquisitions & Divestments was $723.4 million in Q3 2025, compared to $332.5 million in Q2 2025 and $524.4 million in Q1 2025.